Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding

Phase 4 Completed 88 enrolled Hospital General de Mexico

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of this study is to determine whether lactulose, L-ornithine L-aspartate, and rifaximin are effective in the prevention of the development of hepatic encephalopathy in cirrhotic patients with acute variceal bleeding

Timeline

Start: 2014-07
Primary completion: 2016-06
Completion: 2016-06

Publications

Higuera-de-la-Tijera F, Servin-Caamano AI, Salas-Gordillo F, Perez-Hernandez JL, Abdo-Francis JM, Camacho-Aguilera J, Alla SN, Jimenez-Ponce F. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding. Can J Gastroenterol Hepatol. 2018 Jul 10;2018:3015891. doi: 10.1155/2018/3015891. eCollection 2018.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	L-ornithine L-aspartate	Other / unclassified	10 g	Intravenous
Subject	Lactulose	Other / unclassified	30 ml	Oral
Subject	Rifaximin	Other / unclassified	400 mg	—

Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding

Summary

Timeline

Publications

Drugs

Indications